Phase 1 N=32 Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions
Bioequivalence
Primary: Concentration Maximum (Cmax) — 1.326; 1.293 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
Dry Eye Disease
Primary: Mean Change in Schirmer's Test Score From Baseline to 84 Days — 10.8; 11.0; 6.0 mm
N/A N=61 Connecting Alaska Native People to Quit Smoking
Tobacco Use · Tobacco Smoking · Tobacco Use Cessation
Primary: Smoking Cessation Program Completion — 16; 19 Participants
N/A N=199 Evaluating Soft Contact Lens Prototypes for Myopia Control
Visual Acuity
Primary: Axial Length — 0.119; 0.135; 0.079; 0.189 mm
Phase 2 N=12 Effects of Galantamine on Cognition
Schizophrenia
Primary: RVIP Target Hit and False Alarm (Number of Responses) — 23.4; 22.8; 19.7; 14.88 Number of responses — p=0.898
Phase 2 N=121 Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Malignant Glioma · Glioblastoma
Primary: Radiographic Objective Response Rate (ORR) - Part 2 Cohort — 3.3 Percent of participants
N/A N=104 Vacuum-formed Retainer Versus Bonded Retainer to Prevent Relapse After Orthodontic Treatment
Orthodontics · Retention
Primary: Changes in Tooth Position — 0.05; 0.62 millimeters — p=0.0002
Phase 3 N=52 Tranexamic Acid Dosing in Adult Spinal Deformity Surgery
Adult Spinal Deformity
Primary: Blood Loss — 2046; 1596 mL
Phase 1 N=32 Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions
Bioequivalence
Primary: Concentration Maximum (Cmax) — 0.9092; 0.8711 ng/ml
Phase 2 N=51 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Breast Cancer · Breast Cancer, Male · Breast Cancer Female
Primary: Phase 1: Recommended Phase 2 Dose (RP2D) — 75 mcg/m^2
N/A N=20 Hybrid Cochlear Implants in Severe to Profound Adults, Children, and Adolescents
Hearing Loss, High-Frequency
Primary: Change in CNC Word Perception — 27.6; 34; 55.9; 68 percentage of words correct
N/A N=24 Bispectral Index and Levels of Sedation With Propofol With/Without Remifentanil in Healthy Volunteers (SONORA)
Anesthesia
Primary: BIS50 — 60.4; 71.6 BIS50 Index Score
Phase 4 N=40 Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
Gestational Diabetes Mellitus
Primary: Hemoglobin A1C — 5.5; 5.6 A1c percent
Phase 2 N=56 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Thymoma · Thymus Neoplasms
Primary: Percentage of Participants With an Objective Response (Partial Response (PR) + Complete Response (CR) for Sunitinib in Participants With Relapsed or Refractory Thymoma…
Phase 2 N=41 Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Colorectal Neoplasms
Primary: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) — 5.0; 5.0 Percentage of Participants